




## Mouse Anti-Human IgG<sub>3</sub> Hinge

Cat. No.	Format	Size
9210-01	Purified (UNLB)	0.5 mg
9210-02	Fluorescein (FITC)	0.5 mg
9210-04	Alkaline Phosphatase (AP)	1.0 mL
9210-05	Horseradish Peroxidase (HRP)	1.0 mL
9210-08	Biotin (BIOT)	0.5 mg
9210-09	R-phycoerythrin (PE)	0.1 mg
9210-30	Alexa Fluor <sup>®</sup> 488 (AF488)	0.1 mg
9210-31	Alexa Fluor <sup>®</sup> 647 (AF647)	0.1 mg
9210-32	Alexa Fluor <sup>®</sup> 555 (AF555)	0.1 mg



FLISA plate was coated with purified human IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, and IgG<sub>4</sub>. Immunoglobulins were detected with serially diluted Mouse Anti-Human IgG<sub>3</sub> Hinge-FITC (SB Cat. No. 9210-02).

### Overview

<b>Clone</b>	HP6050
<b>Isotype</b>	Mouse (BALB/c) IgG <sub>1κ</sub>
<b>Immunogen</b>	Human IgG <sub>3</sub> myeloma protein
<b>Specificity</b>	Human IgG <sub>3</sub> Hinge; Mr 170 kDa

### Applications

ELISA – Quality tested<sup>2-10,14,16</sup>  
 FLISA – Quality tested  
 ELISPOT – Reported in literature<sup>10</sup>  
 FC – Reported in literature<sup>17,18</sup>  
 IHC-FS – Reported in literature<sup>11,12</sup>  
 IHC-PS – Reported in literature<sup>13,14</sup>  
 WB – Reported in literature<sup>15,16</sup>  
 IP – Reported in literature<sup>1</sup>  
 Multiplex – Reported in literature<sup>19-21</sup>  
 Purification – Reported in literature<sup>3</sup>  
 SPR – Reported in literature<sup>22</sup>

### Working Dilutions

<b>ELISA</b>	Purified (UNLB) antibody	≤ 1 µg/mL
	AP conjugate	1:500 – 1:1,000
	HRP conjugate	1:4,000 – 1:10,000
	BIOT conjugate	1:5,000 – 1:10,000
<b>FLISA</b>	FITC, AF488, and AF555 conjugates	1:200 – 1:400
	PE and AF647 conjugates	≤ 1 µg/mL
<b>Other Applications</b>	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.	

**For Research Use Only. Not for Diagnostic or Therapeutic Use.**

## Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL of stock solution in 50 mM Tris/1 mM MgCl<sub>2</sub>/50% glycerol, pH 8.0, containing NaN<sub>3</sub> as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL of stock solution in 50% glycerol/ 50% PBS, pH 7.4. *No preservative added.* Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN<sub>3</sub> and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Alexa Fluor® 488 (AF488), Alexa Fluor® 555 (AF555) and Alexa Fluor® 647 (AF647) conjugates are supplied as 0.1 mg in 0.2 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

## Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

## References

1. Reimer CB, Phillips DJ, Aloisio CH, Moore DD, Galland GG, Wells TW, et al. Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. *Hybridoma*. 1984;3:263-75. (Immunogen, IP)
2. Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. *J Clin Invest*. 1999;104:73-81. (ELISA)
3. Kobayashi T, van der Pol W, van de Winkel JG, Hara K, Sugita N, Westerdaal NA, et al. Relevance of IgG receptor IIIb (CD16) polymorphism to handling of *Porphyromonas gingivalis*: implications for the pathogenesis of adult periodontitis. *J Periodontol Res*. 2000;35:65-73. (ELISA, Purification)
4. Xu P, Cui Z, Chen M, Hellmark T, Zhao M. Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. *Rheumatology*. 2011;50:1236-43. (ELISA)
5. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. *J Infect Dis*. 2012;206:1836-43. (ELISA)
6. Sabbatini P, Tsuji T, Ferras L, Ritter E, Sedrak C, Tuballes K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. *Clin Cancer Res*. 2012;18:6497-508. (ELISA)
7. Westra J, van Assen S, Wiling KR, Land J, Horst G, de Haan A, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. *Clin Exp Immunol*. 2014;178:40-7. (ELISA)
8. Ferreira AR, Singh B, Cabrera-Mora M, Magri De Souza AC, Queiroz Marques MT, Porto LC, et al. Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of Plasmodium vivax reticulocyte binding protein-1: lack of association with HLA-DRB1\*/DQB1\* in malaria exposed individuals from the Brazilian Amazon. *PLoS One*. 2014;9(8):e105828. (ELISA)
9. Haag S, Schneider N, Mason DE, Tuncel J, Andersson IE, Peters EC, et al. Identification of new citrulline-specific autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis of citrullinated type II collagen. *Arthritis Rheumatol*. 2014;66:1440-9. (ELISA)
10. Næss LM, Aarvak T, Aase A, Oftung F, Høiby E, Sandin R, et al. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. *Vaccine*. 1999;17:754-64. (ELISA, ELISPOT)
11. Greenlee JE, Boyden JW, Pingree M, Brashear HR, Clawson SA, Keeney PM. Antibody types and IgG subclasses in paraneoplastic neurological syndromes. *J Neurol Sci*. 2001;184:131-7. (IHC-FS)
12. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. *J Am Soc Nephrol*. 2001;12:1482-92. (IHC-FS)
13. Qu Z, Liu G, Li J, Wu L, Tan Y, Zheng X, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. *Nephrol Dial Transplant*. 2012;27:1931-7. (IHC-PS)
14. Jia X, Hu S, Chen J, Qu Z, Liu G, Cui Z, et al. The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy. *Kidney Int*. 2014;85:945-52. (ELISA, IHC-PS)
15. Bogdanos D, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of *Mycobacterium gordonae* and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. *J Autoimmun*. 2004;22:353-62. (WB)
16. Bogdanos D, Pusi T, Rust C, Vergani D, Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. *J Hepatol*. 2008;49:466-73. (ELISA, WB)
17. Toyoda C, Suzuki Y, Tsuneyama H, Onodera T, Masuno A, Yabe R, et al. Production of human monoclonal anti-Jk3, recognising an epitope including the Jk<sup>a</sup>/Jk<sup>b</sup> polymorphic site of the Kidd glycoprotein. *Transfus Med*. 2014;24:286-91. (FC)
18. Gao B, Moore C, Porcheray F, Rong C, Abidoglu C, DeVito J, et al. Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. *Am J Transplant*. 2014;14:1581-91. (FC)
19. Hönger G, Hopfer H, Arnold M, Spriewald BM, Schaub S, Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. *Transplantation*. 2011;92:41-7. (Multiplex)
20. Schaub S, Hönger G, Koller MT, Liwski R, Amico P. Determinants of C1q binding in the single antigen bead assay. *Transplantation*. 2014;98:387-93. (Multiplex)
21. Bental A, Tyan DB, Sequeria F, Everly MJ, Gandhi MJ, Cornell LD, et al. Antibody-mediated rejection despite inhibition of terminal complement. *Transpl Int*. 2014;27:1235-43. (Multiplex)
22. Lewis KB, Hughes RJ, Epstein MS, Josephson NC, Kempton CL, Kessler CM, et al. Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. *PLoS One*. 2013;8(5):e61120. (Surface Plasmon Resonance)

Alexa Fluor® 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or [outlicensing@lifetech.com](mailto:outlicensing@lifetech.com).

TB9210

18-Nov-16

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: [info@southernbiotech.com](mailto:info@southernbiotech.com) • Website: [www.southernbiotech.com](http://www.southernbiotech.com)